Analyst Expectations For Zimmer Biomet Holdings's Future
Portfolio Pulse from Benzinga Insights
Analyst ratings for Zimmer Biomet Holdings (NYSE:ZBH) have shown a diverse range from bullish to bearish over the last three months, with recent actions including both upgrades and downgrades. The average 12-month price target for ZBH has increased to $135.0, reflecting a 3.39% rise from the previous target. Zimmer Biomet, a leader in orthopedic reconstructive implants, has shown a revenue growth of 6.3% as of December 31, 2023, but its ROE is below industry standards. Despite this, its net margin and ROA outperform industry averages, and its debt-to-equity ratio is below the industry average, indicating strong financial health.
May 03, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zimmer Biomet Holdings has received mixed analyst ratings, with a recent increase in the average 12-month price target to $135.0. The company's financial performance shows strong revenue growth and net margin, but a below-average ROE.
The increase in the average 12-month price target for ZBH, coupled with its strong financial indicators such as revenue growth and net margin, suggests a positive outlook among analysts. However, the below-average ROE indicates areas of concern that could temper investor enthusiasm. The mixed analyst ratings reflect uncertainty, but the overall positive adjustments in price targets and financial health indicators like the net margin and ROA suggest a potential for stock price appreciation in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100